Oncolytics Biotech (ONCY) Assets Average (2009 - 2026)

Oncolytics Biotech (ONCY) has reported Assets Average for 18 consecutive years, with $7.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 45.81% year-over-year to $7.6 million in Q2 2026; TTM through Jun 2026 was $7.6 million, a 45.81% decrease from a year earlier, with the FY2025 full-year figure at $10.5 million, down 50.22% from the prior year.
• Assets Average was $7.6 million for Q2 2026 at Oncolytics Biotech, down from $9.3 million in the prior quarter.
• Over five years, Assets Average peaked at $35.7 million in Q1 2022 and troughed at $7.6 million in Q2 2026.
• A 5-year average of $22.8 million and a median of $25.0 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average climbed 9.62% in 2023 and slumped 48.75% in 2024, its largest moves.
• Over 5 years, Assets Average stood at $28.7 million in 2022, then grew by 9.62% to $31.4 million in 2023, then tumbled by 48.75% to $16.1 million in 2024, then sank by 42.54% to $9.3 million in 2025, then decreased by 17.65% to $7.6 million in 2026.
• The last three Assets Average figures came in at $7.6 million (Q2 2026), $9.3 million (Q4 2025), and $12.7 million (Q3 2025), per Business Quant data.